Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.
Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL. Guerrero-Zotano AL, et al. Among authors: formisano l. Clin Cancer Res. 2018 Jun 1;24(11):2517-2529. doi: 10.1158/1078-0432.CCR-17-2904. Epub 2018 Mar 26. Clin Cancer Res. 2018. PMID: 29581135 Free PMC article.
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group.
Gampenrieder SP, Dezentjé V, Lambertini M, de Nonneville A, Marhold M, Le Du F, Cortés Salgado A, Alpuim Costa D, Vaz Batista M, Chic Ruché N, Tinchon C, Petzer A, Blondeaux E, Del Mastro L, Targato G, Bertucci F, Gonçalves A, Viret F, Bartsch R, Mannsbart C, Deleuze A, Robert L, Saavedra Serrano C, Gion Cortés M, Sampaio-Alves M, Vitorino M, Pecen L, Singer C, Harbeck N, Rinnerthaler G, Greil R; AGMT Study Group. Gampenrieder SP, et al. ESMO Open. 2023 Feb;8(1):100747. doi: 10.1016/j.esmoop.2022.100747. Epub 2022 Dec 21. ESMO Open. 2023. PMID: 36563519 Free PMC article.
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Rubatto M, Fava P, Stanganelli I, Ribero S, Pigozzo J, Di Giacomo AM, Ridolfi L, Tronconi MC, Trojaniello C, Bersanelli M, Garutti M, Indini A, De Risi I, De Tursi M, Merelli B, Morgese F, Occelli M, Cappellini GCA, Poletto S, Fedele D, Brugnara S, Frisinghelli M, Formisano L, Conca R, Tucci M, Russillo M, Ceroni L, Queirolo P, Targato G, Strippoli S, Mandalà M, Guida M, Quaglino P. Rubatto M, et al. Among authors: formisano l. Eur J Cancer. 2023 Jul;187:25-35. doi: 10.1016/j.ejca.2023.03.020. Epub 2023 Mar 23. Eur J Cancer. 2023. PMID: 37099946
Prevention of cardiovascular complications in elderly cancer patients.
Topa E, Rizza M, Iengo M, Cuomo A, Cicia L, Di Sarro E, Miccio M, Ciaccio G, Luise MC, Formisano L, Bianco R, Carlomagno C, Picardi M, Martinelli E, Napolitano S, Troiani T, Ferrara N, Abete P, Tocchetti CG, Mercurio V. Topa E, et al. Among authors: formisano l. Vascul Pharmacol. 2024 Jun;155:107354. doi: 10.1016/j.vph.2024.107354. Vascul Pharmacol. 2024. PMID: 38985632 No abstract available.
New approach to implement cancer patient care: The valutazione percorso rete oncologica campana (ValPeROC)-experience from an Italian oncology network.
Crispo A, Rivieccio G, Cataldo L, Coluccia S, Luongo A, Coppola E, Grimaldi M, Montagnese C, Nocerino F, D'Errico D, Celentano E, Saviano R, Bastone A, Baglio G, De Angelis C, Ciardiello F, Avallone A, Cassata A, Costanzo R, Morabito A, Maione P, Gridelli C, Cigolari S, Borrelli A, De Placido S, Schiavone F, Bianchi AAM, Pignata S; ValPeROC Group. Crispo A, et al. Eur J Cancer Care (Engl). 2022 Nov;31(6):e13736. doi: 10.1111/ecc.13736. Epub 2022 Oct 25. Eur J Cancer Care (Engl). 2022. PMID: 37039607
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fusciello C, Veneziani BM, De Placido S, Bianco R. D'Amato V, et al. Among authors: formisano l. Br J Cancer. 2014 Jun 10;110(12):2887-95. doi: 10.1038/bjc.2014.241. Epub 2014 May 13. Br J Cancer. 2014. PMID: 24823695 Free PMC article.
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL. Young CD, et al. Among authors: formisano l. Mol Cell Proteomics. 2015 Jul;14(7):1959-76. doi: 10.1074/mcp.M115.049783. Epub 2015 May 7. Mol Cell Proteomics. 2015. PMID: 25953087 Free PMC article. Clinical Trial.
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL. Mayer IA, et al. Among authors: formisano l. Clin Cancer Res. 2017 Jan 1;23(1):26-34. doi: 10.1158/1078-0432.CCR-16-0134. Epub 2016 Apr 28. Clin Cancer Res. 2017. PMID: 27126994 Free PMC article. Clinical Trial.
167 results